Диссертация (1174326), страница 23
Текст из файла (страница 23)
- 110(1). – P. 128–133.70. Ananth C.V., Vintzileos A.M. Ischemic placental disease: epidemiology and riskfactors // Eur J Obstet Gynecol Reprod Biol. – 2011. – 159. - P. 77–82.71. Baergen, R.N. Manual of pathology of the human placenta / R.N. Baergen.
- NewYork: Springer, 2011. – 544 p.72. Banzola I., Farina A., Concu M. Performance of a panel of maternal serum markersin predicting preeclampsia at 11-15 weeks' gestation // Prenat Diagn – 2007. – 27. - P.1005-1010.73. Benirschke, K. Patology of the Human Placenta / K. Benirschke, P. Kaufmann. New York: Springer Verlag., 2006.
– 1050 p.74. Beurett N., Vial Y. Umbilical Doppler, IUGR and neonatal mortality and morbility// Ultrasound Obstet. Gynec. – 2003. - 22 (1). - Р. 31.14275. Biagiotti R., Sgambati E., Brizzi E. Placental morphometry in pregnanciescomplicated by intrauterine growth retardation with absent or reversed end diastolic flowin the umbilical artery // Ital J Anat Embryol. – 1999.
- 104(4). – Р. 201-207.76. Breier G. Angiogenesis in embryonic development-a review // Placenta. – 2000. 21 (Suppl. A). – P. 11-15.77. Brosens J.J., Pijnenborg R., Ivo A. Brosens. The myometrial junctional zone spiralarteries in normal and abnormal pregnancies // Am J Obstet Gynecol. – 2002. - 187 (5).– P.
1416-1423.78. Burton G.J., Charnock-Jones D.S. Placental vascular morphodenesis // Bestpractice&research. – 2000. - l4 (6). P. 953-968.79. Burton G.J., Woods A.W., Jauniaux E., Kingdom J.C. Rheological andphysiological consequences of conversion of the maternal spiral arteries foruteroplacental blood flow during human pregnancy // Placenta. – 2009. - 30 (6). P. 473–482.80.
Cande V.A. Ischemic placental disease: a unifying concept for preeclampsia,intrauterine growth restriction, and placental abruption // Semin Perinatol. – 2014. - 38.– P. 131–132.81. Castellucci M., Kosanke G., Verdenelli F., Huppertz B., Kaufmann P.. Villoussprouting: fundamental mechanisms of human placental development // Hum ReprodUpdate.
– 2000. – 6. – P. 485–494.82. Cerdeira A.S., Karumanchi S.A. Angiogenic factors in preeclampsia and relateddisorders // Cold Spring Harb Perspect Med. – 2012. – 2. P. 56-60.83. Chaiworapongsa T., Romero R., Kim Y.M. et al. Plasma soluble vascularendothelial growth factor receptor-1 concentration is elevated prior to the clinicaldiagnosis of pre-eclampsia // J Matern Fetal Neonatal Med. – 2005. – 17. P. 13-18.84. Chang J.J., Muglia L.J., Macones G.A. Association of early-onset pre-eclampsia infirst pregnancy with normotensive second pregnancy outcomes: a population-based study// BJOG. – 2010. - 117(8). – P.
946–953.14385. Charnock-Jonesc D.S., Kaufmanna P., Mayhewb T.M. Aspects of HumanFetoplacental Vasculogenesis and Angiogenesis. I. Molecular Regulation // Placenta. –2004. – 25. – P. 103-113.86. Chen C.P., Bajoria R., Aplin J.D. Decreased vascularization and cell proliferation inplacentas of intrauterine growth-restricted fetuses with abnormal umbilical artery flowvelocity waveforms // Am J Obstet Gynecol. – 2002.
- 187(3). – P. 764-769.87. Cheng D., Hao Y., Zhou W., Ma Y. Vascular endothelial growth factor +936C/T, 634G/C, -2578C/A and -1154G/A polymorphisms with risk of preeclampsia: a metaanalysis // PLoS One. – 2013. - 8(11). P. 85-88.88. Corrêa R.R.M, Gilio D.B., Cavellani C.L., et al. Placental morphometrical andhistopathology changes in the different clinical presentations of hypertensive syndromesin pregnancy // Archives of Gynecology and Obstetrics. – 2008.
- 277(3). – P. 201–206.89. Coulam C.B., Jeyendran R.S. Vascular endothelial growth factor genepolymorphisms and recurrent pregnancy loss // American Journal of ReproductiveImmunology. – 2008. - 59(4). – P. 301-305.90. Crispi F., Dominguez C., Llurba E., et al. Placental angiogenic growth factors anduterine artery Doppler findings for characterization of different subsets in preeclampsiaand in isolated intrauterine growth restriction // Am J Obstet Gynecol. – 2006. – 195. - P.201–207.91. Dashash M., Pravica V., Hutchinson I. V. Association of sudden infant deathsyndrome with VEGF and IL-6 gene polymorphisms // Human immunology. – 2006. 67(8). – P. 627-633.92. de Vries J.I., van Pampus M.G., Hague W.M., Bezemer P.D.
& Joosten, J.H. Lowmolecular-weight heparin added to aspirin in the prevention of recurrent early-onsetpreeclampsia in women with inheritable thrombophilia: the FRUIT-RCT // Journal ofThrombosis and Haemostasis. – 2012. – 10. – P. 64–72.93. Dekker G.A., Robillard P.Y. Preeclampsia: a couple’s disease with maternal andfetal manifestations // CurrentPharmaceutical Design.
– 2005. - 11(6). – P. 699–710.14494. Di Simone N., Di Nicuolo F., Castellani R., Veglia M., Tersigni C., Silano M.,Tritarelli A., Scambia G., Marana R. Low-molecular-weight heparins induce decidualheparin-binding epidermal growth factor-like growth factor expression and promotesurvival of decidual cells undergoing apoptosis // Fertil Steril. – 2012. - 97(1). – P. 169177.95. Distler J.H., Hirth A., Kurowska-Stolarska M„ Gay R.E., Gay S„ Distler O.Angiogenic and angiostatic factors in the molecular control of angiogenesis // Q. J.
Nucl.Med. – 2003. - 47 (3). – P. 149-161.96. Dodd J.M., McLeod A., Windrim R.C., Kingdom J. Antithrombotic therapy forimproving maternal or infant health outcomes in women considered at risk of placentaldysfunction // Cochrane Database Syst Rev. – 2013. - 24(7). CD006780.97. Dodd J.M., Sahi K., McLeod A., Windrim R.C., Kingdom J.P. Heparin therapy forcomplications of placental dysfunction: a systematic review of the literature // Acta ObstetGynecol Scand. – 2008. - 87(8). – P. 804-811.98. Ducray J.F., Naicker T., Moodley J.
Pilot study of comparative placentalmorphometry in pre-eclamptic and normotensive pregnancies suggests possiblemaladaptations of the fetal component of the placenta // European Journal of ObstetricsGynecology and Reproductive Biology. – 2011. - 156(1). - P. 29–34.99. Figg, W. D. Angiogenesis. An Integrative Approach From Science to Medicine / W.D. Figg, J. Folkman. - New York: Springer, 2008. – 586 p.100.
Egbor M., Ansari T., Morris N., Green C.J., Sibbons P.D. Pre-eclampsia and fetalgrowth restriction: how morphometrically different is the placenta? // Placenta. – 2006. 27(6-7). – P. 727–734.101. Eller A. G., Branch D. W., Nelson L. et al. Vascular endothelial growth factor-Agene polymorphisms in women with recurrent pregnancy loss // Journal of reproductiveimmunology. – 2011.
- 88(1). – P. 48-52.102. Erez O., Romero R., Espinoza J. et al. The change in concentrations of angiogenicand anti-angiogenic factors in maternal plasma between the first and second trimesters in145risk assessment for the subsequent development of preeclampsia and small-forgestational age // J Matern Fetal Neonatal Med. – 2008. – 21.
– P. 279-287.103. Ertan A.K., He J.P., Weickert U., Reitnauer K., Mink D., Tanriverdi H.A., SchmidtW. Placental morphometry in pregnancies with reversed enddiastolic flow in theumbilical artery or fetal aorta // Z Geburtshilfe Neonatol. – 2003. - 207(5). – P. 173-178.104. Evers A.C., van Rijn B.B., van Rossum M.M., Bruinse H.W.
Subsequent pregnancyoutcome after first pregnancy with normotensive early-onset intrauterine growthrestriction at 34 weeks of gestation // Hypertens Pregnancy. – 2011. - 30(1). – P. 37–44.105. Falco M.L., Sivanathan J., Laoreti A., Thilaganathan B., Khalil A. Placentalhistopathology associated with preeclampsia: A systematic review and Meta-Analysis //Ultrasound Obstet Gynecol. – 2017. – 23.
P. 87-89.106. Franco C., Walker M., Robertson J., Fitzgerald B., Keating S., McLeod A. Placentalinfarction and thrombophilia // Obstetrics and Gynecology. - 2011. - 117(4). – P. 929–934.107. Fritchley S.J, Kirby J.A, Ali S.
The antagonism of interferon-gamma (IFN-γ) byheparin: examination of the blockade of class II MHC antigen and heat shock protein-70expression // Clin Exp Immunol. – 2000. - 120(2). – P. 247–252.108. Gathiram P., Moodley J. Pre-eclampsia: its pathogenesis and pathophysiology //Cardiovasc J Afr. – 2016. - 27(2). – P.
71-78.109. Gauster M., Moser G., Orendi K., Huppertz B. Factors involved in regulatingtrophoblast fusion: potential role in the development of preeclampsia // Placenta. - 2009.– 30. – P. 49–54.110. Geva E., Ginzinger D.G., Zaloudek C.J., Moore D.H., Byrne A., Jaffe R.B. Humanplacental vascular development: vasculogenic and angiogenic (branching andnonbranching) transformation is regulated by vascular endothelial growth factor-A,angiopoietin-1, and angiopoietin-2 // J Clin Endocrinol Metab 2002. – 87. – P. 4213–24.111.
Goodman C., Jeyendran R. S., Coulam C. B. Vascular endothelial growth factorgene polymorphism and implantation failure // Reproductive biomedicine online. – 2008.- 16(5). – P. 720-723.146112. Grandone E., Chinni E., Villani M., Sciannamè N., Tiscia G.L., Favuzzi G.,Cappucci F., Petruzzelli F., Margaglione M. Modulation of factors involved in placentalhaemostasis and angiogenesis by low-molecular-weight-heparins // Arch Gynecol Obstet.– 2016. - 294(6). – P. 1323-1329.113.
Greer I.A. Anticoagulants in pregnancy // Journal of Thrombosis and Thrombolysis.– 2006. - 21(1). – P. 57–65.114. Gris, J.C., Chauleur, C., Molinari, N., Mares, P., Fabbro-Peray, P., Quere, I.,Lefrant, J.Y., Haddad, B. & Dauzat, M. Addition of enoxaparin to aspirin for thesecondary prevention of placental vascular complications in women with severe preeclampsia. The pilot randomized controlled NOH-PE trial // Thrombosis andHaemostasis.
– 2011. – 106. – P. 1053–1061.115. Gudmundsson S. Long term outcome of the compromised fetus // Ultrasound Obstet.Gynec. – 2003. - 22 (1). – P. 31.116. Han Ch.S., Paidas M.J. Thrombophilia and the placenta. The placenta fromdevelopment to disease // Wiley Blackwell. – 2011. – P. 253—260.117. Han C.S., Mulla M.J., Brosens J.J., Chamley L.W., Paidas M.J., Lockwood C.J.,Abrahams V.M. Aspirin and heparin effect on basal and antiphospholipid antibodymodulation of trophoblast function // ObstetGynecol. – 2011. - 118(5).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
